{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:52:20Z","timestamp":1768625540461,"version":"3.49.0"},"reference-count":0,"publisher":"Termedia Sp. z.o.o.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"published-print":{"date-parts":[[2021,3,18]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Previous studies have hypothesized Fibroblast growth factor 21 (FGF-21) as a potential biomarker of the inflammation associated to liver diseases, which is also receiving high attention for its potential application concerning the management of obesity and co-morbidities. This study aimed to analyze the response of FGF-21 after a weight loss intervention and the relationships with other putative inflammatory liver biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>Sixty-six obese participants from the RESMENA study were evaluated at baseline and after following a 6-months energy restriction treatment. Anthropometrical, body composition by DXA, routine laboratory measurements, which included transaminases and gamma-glutamyl transferase (GGT) were analyzed by standardized methods. Moreover, FGF-21, M30-fragment (M30) and plasminogen activator inhibitor-1 (PAI-I) were analyzed as recognized liver inflammatory related biomarkers with specific ELISA Kits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Most measurements related with hepatic damage, inflammation and adiposity status improved at the end of the 6-months nutritional intervention. In addition, \u0394FGF-21 shifts evidenced statistical relationships with changes in \u0394M30, \u0394GGT and \u0394PAI.  The reduction of M30 showed significant associations with changes in transaminases. Furthermore, PAI-I changes were related with \u0394M30 and \u0394GGT regardless of weight loss. A linear regression model was set up to assess the influence of \u0394PAI-I and \u0394M30 on the variability of \u0394FGF-21 (23.8%) adjusted by weight loss.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results evidenced interactions of some liver inflammatory mediators, specifically M30 and PAI-I with FGF-21. Thus, more investigation about FGF-21 is required given that this protein could be a biomarker of the obesity-inflammation-liver process.<\/jats:p><\/jats:sec>","DOI":"10.5114\/aoms\/98948","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T22:03:38Z","timestamp":1616450618000},"source":"Crossref","is-referenced-by-count":3,"title":["FGF-21 LEVELS AND LIVER INFLAMMATORY BIOMARKERS IN OBESE SUBJECTS AFTER WEIGHT LOSS."],"prefix":"10.5114","author":[{"given":"Irene","family":"Cantero","sequence":"first","affiliation":[{"name":"Department of Nutrition and Physiology, University of Navarra, Pamplona. Centre for Nutrition Research, University of Navarra, Pamplona."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Abete","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Physiology, University of Navarra, Pamplona. Centre for Nutrition Research, University of Navarra, Pamplona. CIBERobn, Physiopathology of Obesity and Nutrition. Instituto de Salud Carlos III. Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanesa","family":"Bullon-Vela","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Physiology, University of Navarra, Pamplona. Centre for Nutrition Research, University of Navarra, Pamplona."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Belen","family":"Crujeiras","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Cellular Endocrinology, Health Research Insitute of Santiago (IDIS), Univesity Hospital of Santiago (XXIS\/SERGAS), Santiago de Compostela University (USC), Santiago de Compostela, Spain.\nCIBERobn, Physiopathology of Obesity and Nutrition. Instituto de Salud Carlos III. Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.Felipe","family":"Casanueva","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Cellular Endocrinology, Health Research Insitute of Santiago (IDIS), Univesity Hospital of Santiago (XXIS\/SERGAS), Santiago de Compostela University (USC), Santiago de Compostela, Spain.\nCIBERobn, Physiopathology of Obesity and Nutrition. Instituto de Salud Carlos III. Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Angeles","family":"Zulet","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Physiology, University of Navarra, Pamplona. Centre for Nutrition Research, University of Navarra, Pamplona. CIBERobn, Physiopathology of Obesity and Nutrition. Instituto de Salud Carlos III. Spain \nNavarra Institute for Health Research (IdiSNA). Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Alfredo","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Physiology, University of Navarra, Pamplona. Centre for Nutrition Research, University of Navarra, Pamplona. CIBERobn, Physiopathology of Obesity and Nutrition. Instituto de Salud Carlos III. Spain \nNavarra Institute for Health Research (IdiSNA). Spain\nIMDEA food. Madrid. Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2021,3,18]]},"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-98948-62911","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-98948-62911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T20:19:55Z","timestamp":1623442795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/FGF-21-LEVELS-AND-LIVER-INFLAMMATORY-BIOMARKERS-IN-OBESE-SUBJECTS-AFTER-WEIGHT-LOSS,98948,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":0,"alternative-id":["98948"],"URL":"https:\/\/doi.org\/10.5114\/aoms\/98948","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"value":"1734-1922","type":"print"},{"value":"1896-9151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]}}}